1. Scrip
  2. >>Business

Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'

Vaccitech Hails Partner's ‘Aggressive’ Trial Design

 
• By Andrew McConaghie

The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.

Vaccitech
Spun out in 2016, Vaccitech has co-developed with Oxford the adenovirus platform used in the COVID-19 vaccine candidate

AstraZeneca PLC has come on board as a new big pharma partner to help the University of Oxford realise its hugely ambitious plans to have its COVID-19 vaccine ready by September.

The UK-headquartered firm announced on 30 April that it had accepted the challenge to lead late-stage development of the adenovirus-based vaccine named ChAdOx1 nCoV-19, which could become the first to gain approval and broad

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip